The WIN 2012 Symposium, held in  Paris, June 28-29, 2012, was the fourth meeting in the successful series of annual meetings dedicated to personalized cancer medicine.  It attracted over 400 delegates from over 30 countries. The WIN Consortium was created to accelerate the pace and reduce the cost of translating effective cancer treatments to the bedside. The WIN 2012 Symposium provided an open forum for discussion between all stakeholders in cancer biomarkers and therapeutics development and great networking opportunities for everyone involved in improving cancer patient care at the level of the individual patient. 

The main theme of the 2012 symposium, Efficacy of biomarkers and personalized cancer therapeutics, was elaborated in various plenary sessions, which brought together a unique assembly of high-ranking experts from academia, industry and regulatory agencies worldwide as speakers and moderators. 

The quality of the WIN 2012 program has been recognized by several major international organizations. ASCO, ESMO, INCa and UICC which endorsed WIN 2012. Open the PDF "Endorsements WIN 2012" for more information and disclaimers. The program received the qualification "ESMO-labeled meeting" from ESMO.  

"The WIN Consortium meeting reflects the vision and goals of ASCO's blueprint for transforming cancer research and the potential that molecularly-driven therapies have to transform clinical research,” said Sandra Swain, M.D., President of ASCO. “ASCO is pleased to endorse this meeting because of the opportunities it provides for international collaboration.” (Press release, June 4)



Congress by design appointment

WIN CONSORTIUM appoints Congress by design, formerly MCCM Meeting Management, as congress management agency for the 4th WIN symposium in personalized cancer medicine

Read more »